aTyr PharmaATYR -7.26%14 Return-on-Tangible-Asset is -50.00% as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, aTyr Pharma ranks worse than 71.39% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. aTyr Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was $-43.16 Mil. aTyr Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was $86.33 Mil. Therefore, aTyr Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -50.00%.
The historical rank and industry rank for aTyr Pharma's Return-on-Tangible-Asset or its related term are showing as below:
ATYR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -78.09 Med: -50.83 Max: -42.91
Current: -73.24
During the past 13 years, aTyr Pharma's highest Return-on-Tangible-Asset was -42.91%. The lowest was -78.09%. And the median was -50.83%.
ATYR's Return-on-Tangible-Asset is ranked worse than 71.39% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs ATYR: -73.24
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
aTyr Pharma Return-on-Tangible-Asset Related Terms
aTyr Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATYR vs DWTX, CNTX, INKT: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, aTyr Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -50.00% mean?
aTyr Pharma (ATYR) has a Return-on-Tangible-Asset of -50.00% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #1008 out of 1412 companies in the Biotechnology industry, placing it in the top 71.4%.
Is aTyr Pharma's Return-on-Tangible-Asset too high?
aTyr Pharma's current Return-on-Tangible-Asset is -50.00%. Based on the distribution chart, aTyr Pharma ranks #1008 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Return-on-Tangible-Asset compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #1008 out of 1412 companies for Return-on-Tangible-Asset. This places aTyr Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current Return-on-Tangible-Asset is -50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.60 — trading 29.7% above its estimated fair value. The current Return-on-Tangible-Asset is -50.00%. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Return-on-Tangible-Asset is -50.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.60 is trading 29.7% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Significantly Overvalued.
Key valuation signals for ATYR:
Return-on-Tangible-Asset: -50.00%
GF Value™: $0.46 vs. price of $0.60 (29.7% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
